Results 111 to 120 of about 39,387 (293)

The Efficacy of Medical Interventions for Free-Floating Thrombus in Cerebrovascular Events: A Systematic Review

Brain Sciences
Although free-floating thrombus (FFT) poses a significant risk of stroke or transient ischemic attack (TIA), optimal management strategies are uncertain. To determine the state-of-the-art of medical interventions for FFT, we conducted a systematic review
Fairoz Jayyusi, Majd M. AlBarakat, Habib H. Al-Rousan, Mohmmad M. Alawajneh, Abdel Rahman Alkasabrah, Mo’tasem Abujaber, Mohammed E. Aldabbas, Mustafa Abuelsamen, Yahya Alshgerat, Yahia Sayuri, Nazeeh Alhertani, Mohammad BaniAmer, Issa Shari, James Robert Brašić   +13 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Antiplatelets in secondary stroke prevention

Frontiers in Neurology, 2011
The aim of this review is to provide evidence-based recommendations on the secondary prevention of atherothrombotic ischemic stroke. Antiplatelets are the major therapy for the secondary stroke prevention.
Olga eShulga, Natan eBornstein
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents [PDF]

, 2023
Hanxu Li, Jian-Hui Tian, Huayu Li, Xin Wan, Yu Zou   +4 more
openalex   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. [PDF]

, 2019
BackgroundIn non-valvular atrial fibrillation (NVAF) patients, congestive heart failure (CHF) confers an increased risk of stroke or systemic thromboembolism.
Cannon, Christopher P, Castillo, Javier, Contreras, Johanna P, Hong, Kimberly N, Hsu, Jonathan C, Maddox, Thomas M, Marzec, Lucas N, Yang, Song   +7 more
core   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García, Teresa López‐Sobrino, Esther Sanz‐Girgas, Maria R. Cueto, Jaime Aboal, Pablo Pastor, Irene Buera, Alessandro Sionis, Rut Andrea, Judit Rodríguez‐López, Jose Carlos Sánchez‐Salado, Carlos Tomas, Jordi Bañeras, Albert Ariza, Josep Lupón, Antoni Bayés‐Genís, Ferran Rueda, Grup de Treball de Cures Agudes Cardiològiques Societat Catalana de Cardiologia   +17 more
wiley   +1 more source

Resistencia al ácido acetil salicílico y al clopidogrel: una entidad clínica emergente Resistance to acetylsalicylic acid and to clopidogrel: an emergent clinical entity

Revista Colombiana de Cardiología, 2008
El ácido acetil salicílico es quizás uno de los medicamentos más antiguos conocidos en el mundo, desde los tiempos de Hipócrates cuando se consumía la corteza del Sauce por sus efectos analgésicos y antipiréticos.
José J Lugo, Edgar F Hurtado, Luis I Calderón, Germán Gómez, Pablo Castro, Gilberto Estrada, Jaime A Fonseca   +6 more
doaj